Literature DB >> 11728976

Achieving maximal renal protection in nondiabetic chronic renal disease.

M W Taal1, B M Brenner.   

Abstract

A rapid global increase in the number of patients requiring renal replacement therapy necessitates that effective strategies for renal protection are developed and applied widely. We review the experimental and clinical evidence in support of individual renoprotective interventions, including angiotensin-converting enzyme therapy, control of systemic hypertension, dietary protein restriction, reduction of proteinuria, treatment of hyperlipidemia, and smoking cessation. We also consider potential future renoprotective therapies. To achieve maximal renal protection, a comprehensive strategy employing all of these elements is required. This strategy should be directed at normalizing clinical markers of renal disease to induce a state of remission.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728976     DOI: 10.1053/ajkd.2001.29259

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  Losartan reverses glomerular podocytes injury induced by AngII via stabilizing the expression of GLUT1.

Authors:  S Y Yu; R Qi; H Zhao
Journal:  Mol Biol Rep       Date:  2013-09-24       Impact factor: 2.316

2.  Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF.

Authors:  Youli Wang; Kathleen O Heilig; Andrew W Minto; Shenglin Chen; Minghui Xiang; David A Dean; Richard C Geiger; Anthony Chang; Dimitrina D Pravtcheva; Martin Schlimme; Dilip K Deb; Ying Wang; Charles W Heilig
Journal:  Lab Invest       Date:  2009-11-16       Impact factor: 5.662

Review 3.  [Sympathetic overactivity and the kidney].

Authors:  Antje Habicht; Bruno Watschinger
Journal:  Wien Klin Wochenschr       Date:  2003-09-30       Impact factor: 2.275

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.